Author

Shiri Li

Weill Cornell Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Isaac NathooiD· 2 shared Jeshua KimiD· 2 shared Marcus DaSilva GoncalvesiD· 2 shared Mujmmail Ahmed· 2 shared A. M. SalehiD· 1 shared André Lima QueiroziD· 1 shared Anirudh MurthyiD· 1 shared Baran A. ErsoyiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Isaac NathooORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BRCA2 loss drives a PKM1-dominant glycolytic state that is selectively lethal to pyruvate kinase activation

Maira Di Tano, Mujmmail Ahmed, Shiri Li, Michael Lyashenko, Neil G. Ruthen, Ethan Tse, Isaac Nathoo, Carolina E. Echeverría, Jack Sanford, A. M. Saleh, Jeshua Kim, Ezequiel Carlos Dantas, Davide Pradella, Rhee Kyu, Ed Reznik, , Marcus DaSilva Goncalves

The paper shows BRCA2 loss leads to a PKM1-dominant glycolytic state that can be targeted with PKM activators to kill HRD tumors.

bioRxiv · Sep 29, 2026 · PreprintCancer Biology

JAK1/2 Inhibition Delays Cachexia and Improves Survival through Increased Food Intake

Ezequiel Dantas, Anirudh Murthy, Jeshua Kim, Tanvir Ahmed, Mujmmail Ahmed, Tiffany Perrier, Shakti Ramsamooj, Isaac Nathoo, Lucas Kniess Debarba, André Lima Queiroz, Shiri Li, Baran A. Ersoy, Miriam Ferrer, Ido Goldstein, Jonathan Gao, , Marcus DaSilva Goncalves

This study shows that JAK1/2 inhibition with ruxolitinib improves survival and body weight in lung cancer models by increasing food intake and restoring metabolic function.

bioRxiv · Oct 21, 2025 · PreprintCancer Biology